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Introduction
Allogeneic hematopoietic stem cell transplantation (aHSCT) is a curative treatment for many hematological malignancies. Cyclophosphamide (CY) in combination with either ablative doses of total body irradiation (TBI) or the oral alkylating agent busulfan (Bu) is the most common conditioning regimen for aHSCT. 1 However, TBI and CY can induce transplantation-associated coagulopathy (TAC) conditions such as veno-occlusive disease (VOD). 2 Several interactions between coagulation-related blood components and the fibrinolytic system are involved in the progression of vascular angiopathy. Notably, plasminogen activator inhibitor (PAI)-1 plays an important role in the pathophysiology of many vascular abnormalities.
3 PAI-1 levels fluctuate following aHSCT, and increased PAI-1 levels are associated with post-aHSCT complications. 4, 5 Therefore, PAI-1 is a potential predictive marker for VOD following aHSCT. 6 High-mobility group box 1 (HMGB1) is a nuclear protein which binds nucleosomes and promotes DNA bending.
7 HMGB1 plays a crucial role in the cellular response to tissue damage, and is secreted by multiple cell types. 8 HMGB1 expression is detectable in various immune and inflammatory diseases, 9 and it is sequestered by thrombomodulin in vivo. 10 While PAI-1 may play an important role in TAC following aHSCT, a relationship between HMGB1 and PAI-1 following aHSCT has not been
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Nomura et al previously reported. Here, we have investigated levels of HMGB1 and PAI-1 following aHSCT. To our knowledge, this multi-institutional joint study is the first report of the clinical significance of these biomarkers for aHSCT. Blood samples from patients were collected into tubes containing sodium citrate or tubes without any anticoagulant, and the blood was allowed to clot at room temperature for a minimum of 1 hour. Serum or citrated plasma was isolated by centrifugation for 20 minutes at 1,000× g at 4°C. Serum was divided into aliquots and frozen at -30°C until use. HMGB1 was measured using the HMGB1 enzymelinked immunosorbent assay (ELISA) Kit II (Shino-Test Corporation, Kanagawa, Japan). PAI-1 ELISA kits were purchased from BioSource International Inc. (Camarillo, CA, USA). All ELISA kits were used according to the manufacturers' instructions. As a positive control, recombinant proteins were used in each assay alongside the standard solutions that were provided with the commercial kits. Data are expressed as the means ± standard deviation. Comparisons between groups were made using the Student's t-test.
Materials and methods
We calculated the cutoff value for the HMGB1 level at day 0 using receiver operating characteristic curve analysis. This is because HMGB1 levels at day 0 were significantly elevated compared with levels before beginning the conditioning regimen (Table 1) . Finally, patients were divided into two subgroups based on their HMGB1 levels at day 0 after aHSCT. Group A was defined as patients showing a .1.5-fold increase in plasma HMGB1 levels after aHSCT relative to levels before beginning the conditioning regimen. Group B was defined as those with a ,1.5-fold increase in plasma HMGB1. Differences between PAI-1 levels in Groups A and B were evaluated by one-way analysis of variance followed by Dunnett's test. All statistical analyses were performed using StatFlex (version 6) software (Artec Inc., Osaka, Japan), and P,0.05 indicated a statistically significant difference. Table 1 shows the levels of HMGB1 and PAI-1 before and after aHSCT. A significant increase in HMGB1 levels occurred after conditioning treatment, with peak levels observed at day 0 (Table 1) . PAI-1 levels were significantly increased at days 14, 21, and 28 after aHSCT (Table 1) . Figure 1 depicts the elevation of HMGB1 levels at day 0 after aHSCT. The levels of HMGB1 at day 0 were significantly increased in TBI+ patients and CY/TBI patients (TBI+ vs TBI-, 12.7±2.3 vs 10.8±1.4 ng/mL, P,0.01; CY/ TBI vs fludarabine/Bu, 13.3±2.6 vs 12.2±1.1 ng/mL, P,0.01; CY/TBI vs Bu/CY, 13.3±2.6 vs 12.6±0.8 ng/mL, P,0.05; Figure 1 ). Classification of patients by graft source or graft versus host disease prophylaxis did not reveal significant differences between patient groups (Figure 1) .
Results
We divided patients into two subgroups based on HMGB1 levels after aHSCT. Group A (increased HMGB1) had significantly increased plasma PAI-1 levels relative to baseline. Following aHSCT, PAI-1 levels were significantly 
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Relationship between HMGB1 and PAI-1 after aHSCT higher in Group A compared with Group B (two-factor analysis of variance, P,0.05; Figure 2 ).
Discussion
An increased risk of developing TAC is associated with the inclusion of TBI in the conditioning regimen for aHSCT. 1 We identified increased levels of HMGB1 at day 0 in patients treated with conditioning regimens that included TBI or CY. This suggests that HMGB1 may be involved in the development of TAC following conditioning for aHSCT. Cutler et al 6 reported that increased vascular endothelial cell dysfunction is a predictive indicator of VOD. Although the etiology of VOD remains unclear, we suspect that increased levels of proinflammatory cytokines -such as HMGB1 -contribute to VOD. HMGB1 is implicated in the pathophysiology of a variety of inflammatory and immunological diseases. 9, 10 Several previous reports have examined the role of HMGB1 in aHSCT. [11] [12] [13] Tagami et al 11 reported that HMGB1 may play a role during the mobilization of stem cells from the bone marrow into the systemic circulation. Additionally, Yujiri et al 12 suggested that HMGB1 may be a useful marker of acute graft versus host disease. Furthermore, Kornblit et al 13 proposed that an inherited variation in HMGB1 is associated with outcome after aHSCT. However, these previous reports did not examine changes in the level of HMGB1 after aHSCT. Our study details changes in HMGB1 levels postconditioning for aHSCT in a large patient cohort. Our results suggest that increased HMGB1 levels following myeloablative conditioning influence outcome after aHSCT.
PAI-1 is expressed by many cells, including endothelial cells, vascular smooth muscle cells, and platelets. In addition, PAI-1 expression can be regulated by many factors, including cytokines, oxidative stress, and cellular signaling molecules. Moreover, some previous reports have shown that all patients 
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Submit your manuscript here: http://www.dovepress.com/Journal-of-blood-medicine-journal with transplantation-related complications -especially those with thrombotic complications -had significantly increased mean and maximal levels of PAI-1 over the observational period following aHSCT. 5, 6 Thus, PAI-1 is a known potential predictive marker for TAC following aHSCT. In this study, increased HMGB1 levels were associated with a significant increase in plasma PAI-1 levels relative to baseline. Additionally, PAI-1 levels in patients with increased HMGB1 were significantly higher than those in patients without increased HMGB1. These results suggest that increased PAI-1 levels could activate endothelial cells via HMGB1 following aHSCT. However, the development of TAC after aHSCT depends on multiple factors. Therefore, determination of whether PAI-1/HMGB1 levels are associated with TAC after aHSCT requires further validation.
We have demonstrated that a significant increase in HMGB1 level can follow aHSCT-conditioning treatment, with peak levels present at day 0. Additionally, HMGB1 levels correlate with PAI-1 levels after aHSCT. This increased HMGB1 expression may promote PAI-1-related TAC following aHSCT. Further studies employing larger patient cohorts are needed to confirm whether changes in the levels of these markers contribute to TAC following aHSCT.
